Zealand Pharma convenes its Annual General Meeting 2018
Company Announcement - No. 10/2018
Zealand Pharma convenes its Annual General Meeting 2018
Copenhagen, March 22, 2018 - Zealand Pharma A/S ("Zealand") convenes the Company`s ordinary Annual General Meeting to be held on |
Thursday April 19, 2018 at 3.00 pm CET |
at the offices of Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 Copenhagen Ø, Denmark. |
Agenda: |
|
|
|
|
|
|
|
|
|
|
|
|
The Annual General Meeting will be held in English. |
Agenda item no. 4: The board members elected by the General Meeting are elected on an annual basis. All of the incumbent board members are standing for re-election, and the Nomination Committee proposes the re-election of all the members:
|
For further information, please contact:
Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of proprietary medicines in late-stage clinical development focused on specialty gastrointestinal and metabolic diseases. In addition, Zealand has two marketed drugs under license to Sanofi and two compounds in clinical development under license to Boehringer Ingelheim.
10-18_0322 Notice to convene AGM
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zealand Pharma via GlobeNewswire
HUG#2178410